Fig. 9.
18F-FDG PET/CT and 89Zr-rituximab immuno-PET/CT images in patient 2 obtained 6 days after injection with and without a preload of unlabelled rituximab show lower tracer uptake in involved lymph nodes with the preload (white arrows), but higher uptake in less accessible visceral lesions (oesophagus and stomach; blue arrows) resulting in better tumour targeting